www.medicinesforeurope.com Open in urlscan Pro
51.38.37.5  Public Scan

Form analysis
1 forms found in the DOM

GET https://www.medicinesforeurope.com

<form role="search" method="get" id="searchform" class="searchform" action="https://www.medicinesforeurope.com">
  <div>
    <input type="text" value="Search" placeholder="Search" name="s" id="s">
    <!-- <input type="submit" id="searchsubmit" value="Search"> -->
  </div>
</form>

Text Content

 * Who we are
   * Medicines for Europe
   * Purpose and Objectives
   * OUR VALUES
   * STRUCTURE
   * OUR MEMBERS
   * BECOME A MEMBER
   * CODE OF CONDUCT
   * DISCLOSURE
   * JOB OPPORTUNITIES
 * Key topics
   * COVID-19
   * Access
   * INDUSTRIAL POLICY
   * REGULATORY AND LEGAL FRAMEWORK
   * FALSIFIED MEDICINES
   * ENVIRONMENT
   * ANTIMICROBIAL RESISTANCE
   * MEDICINE SHORTAGES
 * Publications
   * Factsheets
   * Infographics
   * Reports
   * Policy
   * Videos
   * Podcast
 * Newsroom
   * Press releases
   * In the news
   * Press kit
 * Contact us


Login
 * 
   Generic medicines
   * 
     Home
   * 
     Who we are
     * 
       Generic medicines Group
     * 
       MISSION AND VISION
     * 
       STRUCTURE
     * 
       MEMBERS
     * 
       BECOME A MEMBER
   * 
     Did you know?
     * 
       Definition
     * 
       THERAPEUTIC AREAS
     * 
       GLOSSARY
     * 
       Q&A
   * 
     What’s new
     * 
       FACTSHEETS
     * 
       POLICY
     * 
       REPORTS
     * 
       VIDEOS
     * 
       INFOGRAPHICS
   * 
     Our 5 pillars
     * 
       Patients
     * 
       QUALITY
     * 
       VALUE
     * 
       SUSTAINABILITY
     * 
       PARTNERSHIP
   * 
     Find out more
     * 
       Related links
     * 
       Contact us
   * 
     Twitter
 * 
   Biosimilar medicines
   * 
     Home
   * 
     Who we are
     * 
       Biosimilar medicines Group
     * 
       MISSION AND VISION
     * 
       STRUCTURE
     * 
       MEMBERS
     * 
       BECOME A MEMBER
   * 
     Did you know?
     * 
       DEFINITION
     * 
       THERAPEUTIC AREAS
     * 
       GLOSSARY
     * 
       Q&A
   * 
     What’s new
     * 
       FACTSHEETS
     * 
       POLICY
     * 
       REPORTS
     * 
       VIDEOS
     * 
       INFOGRAPHICS
     * 
       External resources
   * 
     Our 5 pillars
     * 
       Patients
     * 
       QUALITY
     * 
       VALUE
     * 
       SUSTAINABILITY
     * 
       PARTNERSHIP
   * 
     Find out more
     * 
       Related links
     * 
       Contact us
   * 
     Twitter
 * 
   Value added medicines
   * 
     Home
   * 
     Who we are
     * 
       Value added medicines Group
     * 
       MISSION AND VISION
     * 
       STRUCTURE
     * 
       MEMBERS
     * 
       BECOME A MEMBER
   * 
     Did you know?
     * 
       Environment of value added medicines in Europe
     * 
       Definition
     * 
       THERAPEUTIC AREAS
     * 
       Q&A
   * 
     What’s new
     * 
       Environment of value added medicines in Europe
     * 
       FACTSHEETS
     * 
       POLICY
     * 
       REPORTS
     * 
       VIDEOS
     * 
       INFOGRAPHICS
     * 
       Value Added Medicines award 2019
     * 
       QUOTES
   * 
     Our 5 pillars
     * 
       Patients
     * 
       QUALITY
     * 
       VALUE
     * 
       SUSTAINABILITY
     * 
       PARTNERSHIP
   * 
     Find out more
     * 
       Contact us
 * 
   Events


NEW PRICING MODELS FOR GENERIC MEDICINES TO ENSURE LONG-TERM HEALTHY
COMPETITIVENESS IN EUROPE


OPEN REPORT


STRATEGIC RECOMMENDATIONS


CONVERSATIONS ON EU PHARMA

OPEN PODCAST


ADVANCING MEDICINES REPURPOSING
IN THE EU

OPEN DOCUMENT


CREATING A EUROPEAN ECOSYSTEM

for safe, timely and affordable patient-centric innovation

WHITE PAPER FACTSHEET PRESS RELEASE


FILLING THE GAP:

How off-patent medicines can improve the equity and quality of cancer care

REPORT FACTSHEET PRESS RELEASE


LESSONS LEARNED FROM COVID-19

After several months of crisis, we can discern some of the key lessons learned
from COVID-19 for the future of pharmaceutical policy in Europe.

More details

Watch Webinar




PATIENTS

SUSTAINABILITY

VALUE

PARTNERSHIP

QUALITY
Become a member


WHAT'S NEW

New report reveals need for pricing and reimbursement and procurement reforms to
ensure patient access and healthcare sustainability

Read more
More news
Subscribe to our newsletter


MOST POPULAR

Ready to drive access to medicines

Read more


NEXT EVENTS

18th Biosimilar Medicines Conference
THON HOTEL EU BRUSSELS, 6-7 OCTOBER 2022

4th Value Added Medicines Conference
THON HOTEL EU BRUSSELS, 30 NOVEMBER 2022

View all


DID YOU KNOW?

A generic medicine provides the same quality, safety and efficacy as the
original brand name product.
70% to 80% of all healthcare costs in the EU - an estimated €700 billion - is
currently spent on chronic diseases.
Without generic medicines, Europe would have had to pay €100 bn more in 2014 for
its medicines.
Biosimilar medicines are approved by the same stringent regulatory bodies
authorising all biologic medicines in Europe.
A generic medicine undergoes strict scrutiny before it is licensed and given
market approval by the European or national medicines authorities.
The use of biosimilar medicines is expected to result in overall savings from
11.8 up to 33.4 billion euros for 8 EU countries between 2007 and 2020.
Generic medicines bring down the price of originator drugs through market
competition.
EU approved biosimilar medicines are available for patients in over 60 countries
around the world, and recognised as high quality, safe and effective medicines.
Generic medicines improve the cost-effectiveness of existing therapies.
The entrance of biosimilar filgrastim increased patient access by 44% in the UK
between 2006 and 2013.
Generic medicines increase patient access to high-quality medicines and reduce
expenditure while maintaining the same volume.
Appropriate generic medicines policies can improve medication adherence.
Over 15 European countries have manufacturing sites for biosimilar medicines, or
biosimilar candidates under development or under evaluation.
The Generic Medicines Group is a leading partner for better healthcare for all
EU citizens.
The first worldwide biosimilar medicine is somatropin and it was approved in the
EU in 2006.
Bioequivalence is the key factor in creating a generic medicine.
Our members are devoted to primary care medicines which represent 80% of
healthcare spending.
The first biosimilar monoclonal antibody medicine is infliximab and it was
launched in the EU in 2014.
Generic medicines increase patient access to therapies by driving competition in
the market.
12 biologic medicines with global sales of 78 billion euros in 2014 alone will
lose exclusivity by 2020 in Europe.
Generic medicines manufacturers invest between 7-17% of their turnover in
research and development.
Since 2006, biosimilar medicines have generated more than 400 million patient
days of clinical experience.
Generic medicines are the first line treatment for most chronic diseases such as
diabetes, high cholesterol or hypertension.
The basic scientific principle of biosimilar medicines development is
comparability.
80% of the costs in healthcare systems today are linked to chronic disease.



PUBLICATIONS



Factsheets
View
Infographics
View
Reports
View
Policy
View
Code of conduct
View

View all


VIDEO GALLERY

Annual Medicines for Europe and IGBA Conference 2019
4 April 2019
17th Biosimilar Medicines Conference
16 November 2018
15th Legal Affairs Conference
14 December 2018

View all


PHOTO GALLERY

19th Regulatory and Scientific Affairs Conference
30-31 January 2020
13th Pharmacovigilance Conference
29 January 2020
17th Biosimilar Medicines Conference
28-29 March 2019

View all

x

Stay informed on the latest from
Medicines for Europe

Subscribe to our newsletter

MEMBER OF

 * Contact us
 * Privacy Policy

Medicines for Europe AISBL
Rue d’Arlon 50
1000 Brussels Belgium
T : +32 (0)2 736 84 11

Powered by Big Smile Agency
 Tweet
 Tweet
 Tweet
 LinkedIn
We use cookies to ensure that we give you the best experience on our website. If
you continue to use this site we will assume that you are happy with it.Ok